Navigation Links
Generex Addresses Recent Trading Volume in Shares of its Common Stock
Date:9/12/2012

WORCESTER, Mass. and TORONTO, Sept. 12, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today addressed the unusual high volume of trading in shares of its common stock on the Over-the-Counter Bulletin Board yesterday and today.

The trading did not involve any shares held by current Company officers, directors, insiders, or employees.

Generex management is not aware of any Company developments that might tend to precipitate the unusual and sudden trading activity seen over the last two days.

Next week, Generex management will address Company stockholders regarding the status of initiatives of the Company and its wholly-owned subsidiary, Antigen Express, Inc.

The Company expressly disclaims any obligation in the future to address in public announcements (or otherwise) unusual patterns of trading in its common stock or unusual prices or price swings thereof.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
8. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
9. ACEP Commends Congress For Passing Legislation That Addresses Drug Shortages As Well As "Bath Salts"
10. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
11. Delcath Highlights First Quarter 2012 And Recent Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... The Dentists ... it has signed a letter of intent with Moda to acquire ... Company (NORDIC). , Started by dentists 36 years ago, TDIC focuses exclusively on ...
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s work ... A group of researchers and leaders from Sanford Health were selected to participate ... Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award at ...
(Date:4/28/2016)... ... April 28, 2016 , ... ProText Layouts is a set ... Pro X . With ProText Layouts, video editors can create an energetic typography ... length and scale of texts. Creating text-based videos have never been easier. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... La Sirena Foods provides ... in Central America and is looking to grow their market share in the USA. ... exceptional brand as La Sirena Foods and indirectly with Otis McAllister ...
(Date:4/28/2016)... California (PRWEB) , ... April 28, 2016 , ... ... and accessories, is proud to partner with AquaShieldUSA, the country's oldest waterproof ... patient, clinic and medical supply stores, the largest selection of daily, night, weatherproof ...
Breaking Medicine News(10 mins):